Perspective Therapeutics (CATX) Net Income towards Common Stockholders (2010 - 2026)
Perspective Therapeutics (CATX) posted Net Income towards Common Stockholders of -$28.9 million for Q1 2026, down 5727.43% sequentially from $514000.0 in Q2 2025.
Perspective Therapeutics (CATX) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$28.9 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.4 million (down 5698.16% YoY) and the FY2025 annual result came in at $514000.0, up 154.16% from the prior year.
- Net Income towards Common Stockholders eased to -$28.9 million in Q1 2026 per CATX's latest filing, from $514000.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $514000.0 in Q2 2025 and troughed at -$28.9 million in Q1 2026.
- A 5-year average of -$4.3 million and a median of -$1.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders tumbled 234.06% in 2022, then jumped 204.9% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$2.3 million in 2022, then slumped by 127.82% to -$5.2 million in 2023, then soared by 90.55% to -$490000.0 in 2024, then surged by 204.9% to $514000.0 in 2025, then slumped by 5727.43% to -$28.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$28.9 million, $514000.0, and -$490000.0 for Q1 2026, Q2 2025, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Perspective Therapeutics | 386.32 Mn | 386.32 Mn | - | -26.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 197,000.00 |
| Mar 31, 2026 | -28.93 Mn |
| Jun 30, 2025 | 514,000.00 |
| Jun 30, 2024 | -490,000.00 |
| Mar 31, 2024 | -459,000.00 |
| Dec 31, 2023 | -5.18 Mn |
| Sep 30, 2023 | -784,000.00 |
| Jun 30, 2023 | -1.62 Mn |
| Mar 31, 2023 | -1.47 Mn |
| Dec 31, 2022 | -2.28 Mn |
| Sep 30, 2022 | -7.49 Mn |
| Jun 30, 2022 | -2.08 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -1.60 Mn |
| Sep 30, 2021 | -2.24 Mn |
| Jun 30, 2021 | -1.06 Mn |
| Mar 31, 2021 | -745,000.00 |
| Dec 31, 2020 | -868,000.00 |
| Sep 30, 2020 | -716,000.00 |
| Jun 30, 2020 | -1.19 Mn |